6 Undervalued Biotechnology & Medical Research Stocks for Friday, July 12
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Friday, July 12 based on AAII’s Stock Grades.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jack Gilleland
Eunice Kim
Eunice Kim
Jenna Brashear
| Share Statistics | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.9 | $211.8 | 4% |
|
| Shares Out (Mil) | 2.3 | 55.4 | 9% |
|
| Institutional Ownership | 16.5% | 93.0% | 8% |
|
| Float (Mil) | 1.9 | 41.5 | 6% |
|
| Beta | na | 0.99 | na |
|
| Avg Daily Volume (000s) | 14 | 553 | 19% |
|
| Price Change (52-week) |
(37.1%) | 42.8% | 26% |
|
| Growth | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 49.6% | 13.2% | 96% |
|
| Net Income (5yr) | 24.4% | (10.3%) | 79% |
|
| EPS (5yr) | 37.9% | 15.8% | 87 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (11.0%) | (15.7%) | 57% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $3 | $41 | 4% |
|
| Net Income (TTM) (Mil) | ($4) | ($44) | 34% |
|
| EPS (TTM) | ($1.607) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($35) | 28% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($2) | $147 | 3% |
|
| Valuation | XBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.88 | 2.01 | 22% |
|
| P/E | na | 17.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | XBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.9% | 96% |
|
| Net Margin | (123.7%) | (50.6%) | 7% |
|
| ROA | (64.3%) | (47.4%) | 9% |
|
| ROE | (87.5%) | (53.1%) | 10% |
|
| Liabilities to Assets | 30.1% | 29.7% | 21% |
|
| F-Score | 5 | 3 | 50% |
|
Passing Stock Screens
As of 11/13/2026, from a list of 60 stock screening strategies,
| Performance Since Inception: | 2.6% |
| +/- S&P 500: | -4.8 |
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors